Stock Research for RGLS

RGLS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

RGLS Stock Chart & Research Data

The RGLS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RGLS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


RGLS Due diligence Resources & Stock Charts

The RGLS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RGLS Detailed Price Forecast - CNN Money CNN View RGLS Detailed Summary - Google Finance
Yahoo View RGLS Detailed Summary - Yahoo! Finance Zacks View RGLS Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View RGLS Trends & Analysis - Trade-Ideas Barrons View RGLS Major Holders - Barrons
NASDAQ View RGLS Call Transcripts - NASDAQ Seeking View RGLS Breaking News & Analysis - Seeking Alpha
Spotlight View RGLS Annual Report - CompanySpotlight.com OTC Report View RGLS OTC Short Report - OTCShortReport.com
TradeKing View RGLS Fundamentals - TradeKing Charts View RGLS SEC Filings - Bar Chart
WSJ View Historical Prices for RGLS - The WSJ Morningstar View Performance/Total Return for RGLS - Morningstar
MarketWatch View the Analyst Estimates for RGLS - MarketWatch CNBC View the Earnings History for RGLS - CNBC
StockMarketWatch View the RGLS Earnings - StockMarketWatch MacroAxis View RGLS Buy or Sell Recommendations - MacroAxis
Bullish View the RGLS Bullish Patterns - American Bulls Short Pains View RGLS Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View RGLS Stock Mentions - StockTwits PennyStocks View RGLS Stock Mentions - PennyStockTweets
Twitter View RGLS Stock Mentions - Twitter Invest Hub View RGLS Investment Forum News - Investor Hub
Yahoo View RGLS Stock Mentions - Yahoo! Message Board Seeking Alpha View RGLS Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for RGLS - SECform4.com Insider Cow View Insider Transactions for RGLS - Insider Cow
CNBC View RGLS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RGLS - OTC Markets
Yahoo View Insider Transactions for RGLS - Yahoo! Finance NASDAQ View Institutional Holdings for RGLS - NASDAQ


Stock Charts

FinViz View RGLS Stock Insight & Charts - FinViz.com StockCharts View RGLS Investment Charts - StockCharts.com
BarChart View RGLS Stock Overview & Charts - BarChart Trading View View RGLS User Generated Charts - Trading View


Latest Financial News for RGLS

Regulus Stock Plunges on Cash Concerns Despite Restructuring
Posted on Monday July 09, 2018

Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.


Regulus Announces Strategic Update and Corporate Restructuring
Posted on Thursday July 05, 2018

Efforts Aimed at Extending Cash Runway to mid-2019 LA JOLLA, Calif. , July 5, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development ...


Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities
Posted on Thursday July 05, 2018

Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...


Gaithersburg biotech raising $1M to stop cancer tumors in their tracks
Posted on Tuesday July 03, 2018

Key story highlights: Gaithersburg-based miRecule Inc., which is developing therapeutics for cancers that become drug-resistant, is raising $1 million in seed funding. CEO Anthony Saleh spun the company out of the National Institutes of Health in 2016. Long term, Saleh plans to license its technology to pharmaceutical companies.


Enter a stock symbol to view the stock details.